Dr. Jeffrey Weiss, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 350 Boulevard, Passaic, NJ 07055 Phone: 973-365-4300 |
News Archive
RegeneRx Biopharmaceuticals, Inc. announced today that in a preclinical research paper published in the May 2010 issue of the Journal of Neurosurgery, (online ahead of publication), scientists found that the systemic administration of thymosin beta 4, or Tβ4, significantly reduced brain tissue damage and improved brain function in rats with traumatic brain injury, or TBI.
Health authorities in the U.S. are recommending that doctors keep a close eye on patients taking Ketek for signs of liver problems and to stop treatment if symptoms develop.
"There is a paradox at play when it comes to atrial fibrillation in the Latino population," said Dr. Dawood Darbar.
Despite the promising findings of the PROTECT Pilot study, the larger PROTECT trial found no difference with rolofylline versus placebo with respect of the primary and main secondary end-points of the study. Although more rolofylline patients than placebo patients experienced moderate or marked dyspnea improvement at 24 and 48 hours from randomization, this was counterbalanced by a lack of effect on persistent renal impairment. Lastly, the risk of important neurological events was increased in patients on rolofylline.
› Verified 3 days ago